Floatz logo

Carfilzomib

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue

Amir MortazaviSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
City of Hope Medical Center
Phase 3BBB
DEXAMETHASONE
Izidore Lossos, MD
Phase 2BBB
Fludarabine
UNC Lineberger Comprehensive Cancer Center
Phase 2BB
VINCRISTINE SULFATE
SWOG Cancer Research Network
Phase 2BB

View all 50 →

Same molecule, other indications

Carfilzomib is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
MRDDormant
BB
Indicative ·
64 / 100
View asset →
Stage III Adult Diffuse Large Cell LymphomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →